LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

Search

Penumbra Inc

Geschlossen

BrancheGesundheitswesen

320.7 0.4

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

319.37

Max

321.56

Schlüsselkennzahlen

By Trading Economics

Einkommen

163M

33M

Verkäufe

-11M

375M

KGV

Branchendurchschnitt

73.491

49.888

EPS

0.82

Gewinnspanne

8.695

Angestellte

4,700

EBITDA

-30M

38M

Empfehlungen

By TipRanks

Empfehlungen

Neutral

12-Monats-Prognose

+12.17% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

28. Juli 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-224M

13B

Vorheriger Eröffnungskurs

320.3

Vorheriger Schlusskurs

320.7

Nachrichtenstimmung

By Acuity

50%

50%

154 / 344 Ranking in Healthcare

Penumbra Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

15. Jan. 2026, 13:29 UTC

Akquisitionen, Fusionen, Übernahmen

Boston Scientific to Buy Penumbra for $15 Billion in Cash, Stock -- 2nd Update

15. Jan. 2026, 12:35 UTC

Akquisitionen, Fusionen, Übernahmen

Boston Scientific to Buy Penumbra for $15 Billion in Cash, Stock -- Update

15. Jan. 2026, 12:29 UTC

Akquisitionen, Fusionen, Übernahmen

Boston Scientific to Buy Penumbra for $15 Billion in Cash, Stock

6. Mai 2026, 20:15 UTC

Ergebnisse

Penumbra Not Be Providing Fincl Guidance Due to Pending Acquisition by Boston Scientific >PEN

6. Mai 2026, 20:07 UTC

Ergebnisse

Penumbra 1Q Rev $374.8M >PEN

6. Mai 2026, 20:07 UTC

Ergebnisse

Penumbra 1Q EPS 82c >PEN

25. Feb. 2026, 18:02 UTC

Ergebnisse

Penumbra: Won't Be Providing Financial Guidance for 2026, Citing Proposed Boston Scientific Deal

25. Feb. 2026, 18:01 UTC

Ergebnisse

Penumbra 4Q Rev $385.4M >PEN

25. Feb. 2026, 18:01 UTC

Ergebnisse

Penumbra 4Q Adj EPS $1.18 >PEN

25. Feb. 2026, 18:01 UTC

Ergebnisse

Penumbra 4Q EPS $1.20 >PEN

24. Jan. 2026, 06:18 UTC

Akquisitionen, Fusionen, Übernahmen

Our Boston Scientific Pick Has Stumbled. Acquiring Penumbra Will Help the Stock. -- Barrons.com

15. Jan. 2026, 14:37 UTC

Heiße Aktien

Stocks to Watch Thursday: Goldman Sachs, Boston Scientific, BlackRock -- WSJ

15. Jan. 2026, 13:45 UTC

Akquisitionen, Fusionen, Übernahmen

Penumbra Stock Jumps. It's Being Bought by Boston Scientific for $14.5 Billion. -- Barrons.com

15. Jan. 2026, 12:04 UTC

Akquisitionen, Fusionen, Übernahmen

Boston Scientific: Penumbra Shareholders Can Elect to Receive Cash or Stock >BSX PEN

15. Jan. 2026, 12:03 UTC

Akquisitionen, Fusionen, Übernahmen

Boston Scientific: Acquisition to Expand Cardiovascular Portfolio >BSX PEN

15. Jan. 2026, 12:01 UTC

Akquisitionen, Fusionen, Übernahmen

Boston Scientific: Penumbra Deal Carriers an Enterprise Value of About $14.5 Billion >BSX

15. Jan. 2026, 12:00 UTC

Akquisitionen, Fusionen, Übernahmen

Boston Scientific to Buy Penumbra for $374/Share >BSX PEN

15. Jan. 2026, 12:00 UTC

Akquisitionen, Fusionen, Übernahmen

Boston Scientific Announces Agreement To Acquire Penumbra, Inc. >BSX PEN

Peer-Vergleich

Kursveränderung

Penumbra Inc Prognose

Kursziel

By TipRanks

12.17% Vorteil

12-Monats-Prognose

Durchschnitt 358.25 USD  12.17%

Hoch 374 USD

Tief 335 USD

Basierend auf 4 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Penumbra Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

4 ratings

1

Buy

3

Halten

0

Sell

Stimmung

By Acuity

154 / 344 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Penumbra Inc

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX Select, BENCHMARK, BMX96, BMX81, DDC, SENDit, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization Device, aspiration tubing, and aspiration pump under the Penumbra RED, JET, ACE, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as Penumbra SMART COIL, a detachable coil to treat patients with a wide range of neurovascular lesions; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers an immersive 3D computer-based technology platform under the real immersive system brand; and neurosurgical tools, such as Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.
help-icon Live chat